According to the research report titled, 'Transcriptome Sequencing Market Size, Share, Trends, Growth Opportunities & Forecast by Product & Service (Consumables, Instruments, Software & Services), Technology, Application, End User, and Region - Global Forecast (2025-2035),' the transcriptome sequencing market is projected to reach $11.8 billion by 2035, at a CAGR of 7.3% during the forecast period 2025-2035. The report provides an in-depth analysis of the global transcriptome sequencing market across five major regions, emphasizing the current market trends, market sizes, recent developments, and forecasts till 2035.
Succeeding extensive secondary and primary research and an in-depth analysis of the market scenario, the report conducts the impact analysis of the key industry drivers, restraints, opportunities, and challenges. The growth of this market is driven by declining sequencing costs and increasing throughput capacity, rising adoption of precision medicine and companion diagnostics, growing demand for single-cell and spatial transcriptomics applications, and increasing investment in drug discovery and biomarker development programs. Moreover, the integration of AI and machine learning in transcriptome data analytics, expanding applications of long-read sequencing for full-length transcript analysis, and increasing use in clinical diagnostics and liquid biopsy applications are expected to support the market's growth.
The key players operating in the transcriptome sequencing market are Illumina, Inc. (USA), Thermo Fisher Scientific Inc. (USA), Pacific Biosciences of California, Inc. (USA), Oxford Nanopore Technologies plc (U.K.), 10x Genomics, Inc. (USA), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (USA), F. Hoffmann-La Roche Ltd (Switzerland), Bio-Rad Laboratories, Inc. (USA), Takara Bio Inc. (Japan), Becton, Dickinson and Company (USA), Standard BioTools Inc. (USA), Element Biosciences, Inc. (USA), MGI Tech Co., Ltd. (China), Singular Genomics Systems, Inc. (USA), and others.
The transcriptome sequencing market is segmented by product & service (consumables, instruments, and software & services), technology (bulk RNA-seq, single-cell RNA-seq, spatial transcriptomics, long-read RNA sequencing, and small RNA sequencing), application (drug discovery & development, clinical diagnostics, personalized medicine & companion diagnostics, basic & translational research, agricultural & veterinary research, and other applications), end user (pharmaceutical & biotechnology companies, academic & research institutes, clinical diagnostic laboratories, contract research organizations & sequencing service providers, and other end users), and geography. The study also evaluates industry competitors and analyzes the market at the country level.
Based on product and service, the consumables segment made up the largest part of the transcriptome sequencing market in 2025. This segment's leading position comes from the need to continually purchase reagents and kits for ongoing sequencing operations. Researchers frequently use high-quality reagents in transcriptome studies for both research and clinical purposes. The growth of sequencing applications in pharmaceutical, biotechnology, and academic research sectors also contributes to this dominance. Consumables create a steady revenue stream since they must be restocked for each sequencing experiment, unlike instruments that only require a one-time investment. This segment includes RNA extraction kits, library preparation reagents, sequencing chemistry consumables, quality control materials, and sample preparation supplies. The rising use of NGS-based RNA sequencing, single-cell transcriptomics, and spatial transcriptomics applications is significantly increasing the consumption of reagents for each experiment. New library preparation chemistries, reagent kits compatible with automation, and specialized consumables designed for low-input samples and single-cell applications are expanding opportunities in the market. Key players are consistently introducing innovative consumables to keep up with changing researcher needs. For example, QIAGEN will launch the QIAseq Multimodal DNA/RNA Library Kit in May 2024. This kit allows researchers to prepare both DNA and RNA libraries from a single sample, which improves workflow efficiency and reduces sample requirements.
Based on technology, the bulk RNA-seq segment accounted for the largest share of the transcriptome sequencing market in 2025. Its significant market share comes from the fact that bulk RNA-seq is the most established, standardized, and cost-effective transcriptomic technology available today. It has been widely adopted in academic research, pharmaceutical research and development, and clinical studies due to its reliable workflows, reproducibility, and easier data analysis compared to newer single-cell and spatial technologies. Bulk RNA-seq enables high-throughput gene expression profiling across large sample sets, making it suitable for population-level studies, biomarker discovery, toxicology assessments, and drug response analysis. This technology provides broad transcriptome coverage at a much lower cost than single-cell or spatial methods, making it available to more research institutions and applications. Established protocols, extensive validation data, and well-developed bioinformatics tools support its ongoing dominance, particularly in applications where cellular differences aren’t the main focus or where tissue-level average expression is enough for biological insights.
Based on application, the drug discovery and development segment is expected to account for the largest share of the transcriptome sequencing market in 2025. This segment's leading position comes from the way pharmaceutical and biotechnology companies extensively use RNA sequencing technologies for target identification and validation, biomarker discovery, mechanism-of-action studies, toxicogenomics assessments, and stratification of patients in clinical trials. The technology allows for more accurate gene expression profiling, which helps develop targeted therapies, especially in cancer, neurology, immunology, and rare diseases. Transcriptomic data has become a valuable asset throughout the drug development lifecycle, from early target discovery to late-stage clinical development and post-market monitoring. Companies use RNA sequencing to explore disease biology at the molecular level, identify druggable targets, confirm therapeutic mechanisms, predict drug responses, and group patients for tailored medicine approaches. The integration of transcriptome sequencing into companion diagnostic development, particularly for targeted cancer therapies and immunotherapies, strengthens this segment's market leadership, as regulators increasingly require molecular profiling to aid in treatment selection and patient stratification.
Based on end user, the pharmaceutical and biotechnology companies segment accounted for the largest share of the transcriptome sequencing market in 2025. This segment's notable market share is due to the heavy use of transcriptomic data at all stages of drug development, from basic research and target discovery to preclinical development, clinical trials, and post-approval studies. These companies maintain strong in-house genomics capabilities while also working with specialized sequencing service providers for large projects and innovative applications. The pharmaceutical industry's emphasis on precision medicine, targeted therapies, and biomarker-driven development creates a steady demand for advanced transcriptome sequencing solutions. Companies use bulk RNA sequencing for extensive expression studies, single-cell RNA sequencing to understand cellular differences in disease models, spatial transcriptomics to map tumor microenvironments and tissue structure, and long-read sequencing to characterize entire transcript isoforms and fusion events. Combining transcriptomics with other omics datasets allows for thorough molecular characterization that supports drug discovery, patient stratification, biomarker validation, and regulatory applications. Major pharmaceutical companies are also investing heavily in building their own bioinformatics and computational biology capabilities to make the most of transcriptomic data.
An in-depth geographical analysis of the industry offers detailed qualitative and quantitative insights into five major regions: North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. North America held the largest share of the overall transcriptome sequencing market in 2025. This dominance is due to the region's early adoption of advanced genomic technologies, a strong life sciences ecosystem, ongoing investment in biomedical research, and substantial public and private research funding. The region has a high concentration of pharmaceutical and biotechnology companies, leading academic institutions, and major sequencing technology providers, which collectively drive continuous demand for transcriptome sequencing services and products. The United States leads the world in genomics research infrastructure, with significant funding from organizations like the National Institutes of Health and the National Cancer Institute supporting large genomics projects and population health studies. The region benefits from established regulatory paths for genomic diagnostics, strong protection for intellectual property, advanced healthcare systems that incorporate molecular testing, and active collaborations between academia and industry that speed up the translation of technology from research to clinical applications. North America's concentration of innovators in sequencing technology, such as Illumina, Thermo Fisher Scientific, Pacific Biosciences, and 10x Genomics, ensures early access to cutting-edge platforms and ongoing technological progress.
Succeeding extensive secondary and primary research and an in-depth analysis of the market scenario, the report conducts the impact analysis of the key industry drivers, restraints, opportunities, and challenges. The growth of this market is driven by declining sequencing costs and increasing throughput capacity, rising adoption of precision medicine and companion diagnostics, growing demand for single-cell and spatial transcriptomics applications, and increasing investment in drug discovery and biomarker development programs. Moreover, the integration of AI and machine learning in transcriptome data analytics, expanding applications of long-read sequencing for full-length transcript analysis, and increasing use in clinical diagnostics and liquid biopsy applications are expected to support the market's growth.
The key players operating in the transcriptome sequencing market are Illumina, Inc. (USA), Thermo Fisher Scientific Inc. (USA), Pacific Biosciences of California, Inc. (USA), Oxford Nanopore Technologies plc (U.K.), 10x Genomics, Inc. (USA), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (USA), F. Hoffmann-La Roche Ltd (Switzerland), Bio-Rad Laboratories, Inc. (USA), Takara Bio Inc. (Japan), Becton, Dickinson and Company (USA), Standard BioTools Inc. (USA), Element Biosciences, Inc. (USA), MGI Tech Co., Ltd. (China), Singular Genomics Systems, Inc. (USA), and others.
The transcriptome sequencing market is segmented by product & service (consumables, instruments, and software & services), technology (bulk RNA-seq, single-cell RNA-seq, spatial transcriptomics, long-read RNA sequencing, and small RNA sequencing), application (drug discovery & development, clinical diagnostics, personalized medicine & companion diagnostics, basic & translational research, agricultural & veterinary research, and other applications), end user (pharmaceutical & biotechnology companies, academic & research institutes, clinical diagnostic laboratories, contract research organizations & sequencing service providers, and other end users), and geography. The study also evaluates industry competitors and analyzes the market at the country level.
Based on product and service, the consumables segment made up the largest part of the transcriptome sequencing market in 2025. This segment's leading position comes from the need to continually purchase reagents and kits for ongoing sequencing operations. Researchers frequently use high-quality reagents in transcriptome studies for both research and clinical purposes. The growth of sequencing applications in pharmaceutical, biotechnology, and academic research sectors also contributes to this dominance. Consumables create a steady revenue stream since they must be restocked for each sequencing experiment, unlike instruments that only require a one-time investment. This segment includes RNA extraction kits, library preparation reagents, sequencing chemistry consumables, quality control materials, and sample preparation supplies. The rising use of NGS-based RNA sequencing, single-cell transcriptomics, and spatial transcriptomics applications is significantly increasing the consumption of reagents for each experiment. New library preparation chemistries, reagent kits compatible with automation, and specialized consumables designed for low-input samples and single-cell applications are expanding opportunities in the market. Key players are consistently introducing innovative consumables to keep up with changing researcher needs. For example, QIAGEN will launch the QIAseq Multimodal DNA/RNA Library Kit in May 2024. This kit allows researchers to prepare both DNA and RNA libraries from a single sample, which improves workflow efficiency and reduces sample requirements.
Based on technology, the bulk RNA-seq segment accounted for the largest share of the transcriptome sequencing market in 2025. Its significant market share comes from the fact that bulk RNA-seq is the most established, standardized, and cost-effective transcriptomic technology available today. It has been widely adopted in academic research, pharmaceutical research and development, and clinical studies due to its reliable workflows, reproducibility, and easier data analysis compared to newer single-cell and spatial technologies. Bulk RNA-seq enables high-throughput gene expression profiling across large sample sets, making it suitable for population-level studies, biomarker discovery, toxicology assessments, and drug response analysis. This technology provides broad transcriptome coverage at a much lower cost than single-cell or spatial methods, making it available to more research institutions and applications. Established protocols, extensive validation data, and well-developed bioinformatics tools support its ongoing dominance, particularly in applications where cellular differences aren’t the main focus or where tissue-level average expression is enough for biological insights.
Based on application, the drug discovery and development segment is expected to account for the largest share of the transcriptome sequencing market in 2025. This segment's leading position comes from the way pharmaceutical and biotechnology companies extensively use RNA sequencing technologies for target identification and validation, biomarker discovery, mechanism-of-action studies, toxicogenomics assessments, and stratification of patients in clinical trials. The technology allows for more accurate gene expression profiling, which helps develop targeted therapies, especially in cancer, neurology, immunology, and rare diseases. Transcriptomic data has become a valuable asset throughout the drug development lifecycle, from early target discovery to late-stage clinical development and post-market monitoring. Companies use RNA sequencing to explore disease biology at the molecular level, identify druggable targets, confirm therapeutic mechanisms, predict drug responses, and group patients for tailored medicine approaches. The integration of transcriptome sequencing into companion diagnostic development, particularly for targeted cancer therapies and immunotherapies, strengthens this segment's market leadership, as regulators increasingly require molecular profiling to aid in treatment selection and patient stratification.
Based on end user, the pharmaceutical and biotechnology companies segment accounted for the largest share of the transcriptome sequencing market in 2025. This segment's notable market share is due to the heavy use of transcriptomic data at all stages of drug development, from basic research and target discovery to preclinical development, clinical trials, and post-approval studies. These companies maintain strong in-house genomics capabilities while also working with specialized sequencing service providers for large projects and innovative applications. The pharmaceutical industry's emphasis on precision medicine, targeted therapies, and biomarker-driven development creates a steady demand for advanced transcriptome sequencing solutions. Companies use bulk RNA sequencing for extensive expression studies, single-cell RNA sequencing to understand cellular differences in disease models, spatial transcriptomics to map tumor microenvironments and tissue structure, and long-read sequencing to characterize entire transcript isoforms and fusion events. Combining transcriptomics with other omics datasets allows for thorough molecular characterization that supports drug discovery, patient stratification, biomarker validation, and regulatory applications. Major pharmaceutical companies are also investing heavily in building their own bioinformatics and computational biology capabilities to make the most of transcriptomic data.
An in-depth geographical analysis of the industry offers detailed qualitative and quantitative insights into five major regions: North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. North America held the largest share of the overall transcriptome sequencing market in 2025. This dominance is due to the region's early adoption of advanced genomic technologies, a strong life sciences ecosystem, ongoing investment in biomedical research, and substantial public and private research funding. The region has a high concentration of pharmaceutical and biotechnology companies, leading academic institutions, and major sequencing technology providers, which collectively drive continuous demand for transcriptome sequencing services and products. The United States leads the world in genomics research infrastructure, with significant funding from organizations like the National Institutes of Health and the National Cancer Institute supporting large genomics projects and population health studies. The region benefits from established regulatory paths for genomic diagnostics, strong protection for intellectual property, advanced healthcare systems that incorporate molecular testing, and active collaborations between academia and industry that speed up the translation of technology from research to clinical applications. North America's concentration of innovators in sequencing technology, such as Illumina, Thermo Fisher Scientific, Pacific Biosciences, and 10x Genomics, ensures early access to cutting-edge platforms and ongoing technological progress.
Key Questions Answered in the Report:
- What is the current revenue generated by the transcriptome sequencing market globally?
- At what rate is the global transcriptome sequencing demand projected to grow for the next 5-10 years?
- What are the historical market sizes and growth rates of the global transcriptome sequencing market?
- What are the major factors impacting the growth of this market at the regional and country levels? What are the major opportunities for existing players and new entrants in the market?
- Which segments in terms of product & service, technology, application, and end user are expected to create major traction for the manufacturers in this market?
- What are the key geographical trends in this market? Which regions/countries are expected to offer significant growth opportunities for the manufacturers operating in the global transcriptome sequencing market?
- Who are the major players in the global transcriptome sequencing market? What are their specific product offerings in this market?
- What are the recent strategic developments in the global transcriptome sequencing market? What are the impacts of these strategic developments on the market?
Scope of the Report:
Transcriptome Sequencing Market Assessment - by Product & Service
- Consumables
- Instruments
- Software & Services
Transcriptome Sequencing Market Assessment - by Technology
- Bulk RNA-seq
- Single-cell RNA-seq
- Spatial Transcriptomics
- Long-read RNA Sequencing
- Small RNA Sequencing
Transcriptome Sequencing Market Assessment - by Application
- Drug Discovery & Development
- Clinical Diagnostics
- Personalized Medicine & Companion Diagnostics
- Basic & Translational Research
- Agricultural & Veterinary Research
- Other Applications
Transcriptome Sequencing Market Assessment - by End User
- Pharmaceutical & Biotechnology Companies
- Academic & Research Institutes
- Clinical Diagnostic Laboratories
- Contract Research Organizations (CROs) & Sequencing Service Providers
- Other End Users
Transcriptome Sequencing Market Assessment - by Geography
North America
- U.S.
- Canada
Europe
- U.K.
- Germany
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- India
- Japan
- South Korea
- Australia
- Rest of Asia-Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa
- Saudi Arabia
- UAE
- South Africa
- Rest of Middle East & Africa
Table of Contents
1 Introduction
2 Research Methodology
4 Market Insights
5 Global Transcriptome Sequencing Market, By Product & Service
6 Global Transcriptome Sequencing Market, By Technology
7 Global Transcriptome Sequencing Market, By Application
8 Global Transcriptome Sequencing Market, By End User
9 Transcriptome Sequencing Market Assessment, By Geography
10 Competitive Landscape
11 Company Profiles
12 Appendix
Companies Mentioned
- Illumina Inc.
- Thermo Fisher Scientific Inc.
- Pacific Biosciences of California Inc.
- Oxford Nanopore Technologies plc
- 10x Genomics Inc.
- QIAGEN N.V.
- Agilent Technologies Inc.
- F. Hoffmann-La Roche Ltd
- Bio-Rad Laboratories Inc.
- Takara Bio Inc.
- Becton
- Dickinson and Company
- Standard BioTools Inc.
- Element Biosciences Inc.
- MGI Tech Co. Ltd.
- Singular Genomics Systems Inc.
